Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer

NCT02316002 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Oligometastatic Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Pembrolizumab

Sponsor

Abramson Cancer Center at Penn Medicine